We invite your proposals for collaborative research relating to technologies for stem cell drugs, oligonucleotide therapeutics or gene therapy.
Stem cell drugs
- Techniques for in vivo or ex vivo cell functional analysis on differentiated stem cells after transplantation.
- Technologies for improving stem cell implantation at a local administration site or delivering stem cells to a specific target tissue.
- Technology capable of controlling cell survival after in vivo transplantation.
Oligonucleotide therapeutics
- DDS technologies for systemic administration that enable delivery to a target tissue (especially the lung, heart, intestinal tract or central nervous system) with reduced liver transfer rates.
- DDS technologies to improve cell permeability of nucleic acids.
- Technologies to reduce toxicity of nucleic acids.
Gene therapy
- DDS technologies for non-viral vectors with high gene transfer efficiency.
- Technologies that enable regulation of target gene expression in vivo (excluding viral vector-based technologies).